An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma
Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), O. Dereure(Beth Israel Deaconess Medical Center), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), A. Szenik(Centre Hospitalier Universitaire de Besançon), Célèste Lebbé(Inserm), Thierry Lesimple, G. Jeudy(CHU Dijon Bourgogne), L. Machet(Université de Tours), F. Aubin, Florent Grange(Centre Hospitalier Universitaire de Reims), Jean‐Jacques Grob, A. Denden(Novartis (France)), Laurent Mortier, Caroline Robert(Centre National de la Recherche Scientifique), Brigitte Dréno(Inserm), Eve‐Marie Neidhardt(Centre Léon Bérard), C. Bédane(Central Michigan University)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k